SCHEMBL353478

SCHEMBL353478

O=C(O)CCCCCn1c2ccccc2c(=O)c2cc(F)ccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 3/20 0.64
FABP5 Q01469 3/20 0.64
MAPT P10636 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
RXFP1 Q9HBX9 2/20 0.55
HDAC1 Q13547 4/20 0.51
HDAC6 Q9UBN7 4/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
FABP3 P05413 1/20 0.50
GLA P06280 1/20 0.49
SLC6A4 P31645 2/20 0.47
SLC6A2 P23975 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1415661 0.91 FABP4 (0.54) FABP4FABP5MAPTSMN1; SMN2RXFP1
SCHEMBL355352 0.88 FABP4 (0.82) FABP4FABP5MAPTSMN1; SMN2HDAC1
SCHEMBL354539 0.85 FABP4 (0.64) FABP4FABP5MAPTSMN1; SMN2RXFP1
SCHEMBL354562 0.85 FABP4 (0.64) FABP4FABP5MAPTSMN1; SMN2HDAC1
SCHEMBL354801 0.84 RXFP1 (0.55) MAPTSMN1; SMN2RXFP1HDAC1HDAC6
SCHEMBL1415802 0.83 FABP4 (0.64) FABP4FABP5MAPTSMN1; SMN2HDAC1
SCHEMBL353874 0.82 FABP4 (0.60) FABP4FABP5HDAC1HDAC6HDAC3
SCHEMBL5665761 0.82 FABP4 (0.60) FABP4FABP5MAPTSMN1; SMN2HDAC1
SCHEMBL355757 0.82 FABP4 (0.60) FABP4FABP5MAPTSMN1; SMN2HDAC1
SCHEMBL6419189 0.81 FABP4 (0.97) FABP4FABP5HDAC1HDAC6FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-8034558-B2 Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA GE HEALTHCARE UK LIMITED (GB) 2011-10-11 US disclosed
US-8034558-B2 Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA GE HEALTHCARE UK LIMITED (GB) 2011-10-11 US disclosed
US-8034558-B2 Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA GE HEALTHCARE UK LIMITED (GB) 2011-10-11 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20040191792-A1 Acridone derivatives as labels for fluorescence detection of target materials GE HEALTHCARE UK LIMITED (GB) 2004-09-30 US disclosed
EP-1392776-A2 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS Amersham Biosciences UK Limited (GB) 2004-03-03 EP disclosed
WO-2002099424-A2 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS AMERSHAM BIOSCIENCES UK LIMITED (GB) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS ACR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ARSA FABP4 1977/4885FABP5 2935/4885MAPT 4659/4885
US-20040191792-A1 Acridone derivatives as labels for fluorescence detection of target materials ACR, ARSA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 FABP4 1027/4885FABP5 905/4885MAPT 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.